Broadly neutralizing antibodies (bNAbs) are among the most promising new treatments for HIV, offering the potential to forego traditional daily dose of antiretroviral drugs.
The rate of HIV infection continues to climb globally. Around 40 million people live with HIV-1, the most common HIV strain. While symptoms can now be better managed with lifelong treatment, there is ...
New HIV research reveals how broadly neutralizing antibodies may transform treatment despite the virus's rapid mutation and ...
Victor Appay, PhD, explains how long-term ART slows immune aging, boosting HIV viral suppression and paving the way for remission without therapy. For years, HIV has been synonymous not only with ...
University of Delaware professor Juan Perilla (right), is co-author of a new paper that reveals a previously unknown structural role for integrase, a key HIV protein, earlier in the virus' life cycle ...
Gilead’s Tomas Cihlar and his team of researchers have spent decades studying HIV—and their latest innovation could be a game ...
Researchers addressed the need for long-term expression of CCR5-specific antibodies to establish protection from HIV using ...
Share on Pinterest The Trump administration’s plan to cut funding for HIV vaccine research comes at a time when the field is making progress. Victor Torres/Stocksy United The Trump administration ...
Share on Pinterest Metformin, a common medication used to treat type 2 diabetes, may also help reduce the viral reservoir in people living with HIV who are undergoing antiretroviral therapy. Francis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results